Norbert Bischofberger - Gilead Sciences Insider

GILD -- USA Stock  

USD 77.12  0.08  0.10%

Chief Scientific Officer and Executive VP of RandD
Dr. Norbert W. Bischofberger, Ph.D., is no longer Executive Vice President Research and Development, Chief Scientific Officer of Gilead Sciences Inc effective April 30 2018
Age: 60  EVP Since 2007  Ph.D    
650-574-3000  http://www.gilead.com
Bischofberger joined Gilead in 1990 and has served as Executive Vice President, Research and Development since 2000 and Chief Scientific Officer since 2007. Prior to joining Gilead, Dr. Bischofberger was a Senior Scientist in Genentech, Inc.?s DNA Synthesis group from 1986 to 1990. He received his Ph.D. in Organic Chemistry at the Eidgenossische Technische Hochschule in Zurich, Switzerland and performed postdoctoral research in steroid chemistry at Syntex. He also performed additional research in organic chemistry and applied enzymology in Professor George Whiteside?s lab at Harvard University in Cambridge, Massachusetts.

Norbert Bischofberger Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 13.0 % which means that it generated profit of $13.0 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 16.76 % meaning that it created $16.76 on every $100 dollars invested by stockholders.
The company currently holds 29.05 B in liabilities with Debt to Equity (D/E) ratio of 140.6 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Gilead Sciences has Current Ratio of 2.78 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Entity Summary

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company was founded in 1987 and is headquartered in Foster City, California. Gilead Sciences operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 10000 people.Gilead Sciences (GILD) is traded on BATS Exchange in USA. It is located in CALIFORNIA U.S.A and employs 10,000 people. Gilead Sciences is listed under Pharmaceutical Products category by Fama And French industry classification.

Gilead Sciences Leadership Team

Kathleen Watson, President
John McHutchison, President
Andrew Cheng, President
John Martin, Chairman, MBA
Andrew Dickinson, President
Gayle Wilson, Director
Jacqueline Barton, Director, Ph.D
Brett Pletcher, EVP
William Lee, President
John Madigan, Director
Martin Silverstein, President, MBA
Kevin Lofton, Director
Paul Carter, President
Gregg Alton, EVP
Carla Hills, Director, MBA
John Cogan, Director
John Milligan, COO, Ph.D
Nicholas Moore, Director
James Meyers, President
Kelly Kramer, Director
Robin Washington, CFO, MBA
Norbert Bischofberger, EVP, Ph.D
Per WoldOlsen, Director
Harish Manwani, Director
Taiyin Yang, President, Ph.D
Kevin Young, COO
Etienne Davignon, Director
Richard Whitley, Director

Stock Performance Indicators

Did you try this?

Run Portfolio Quick Import Now
   

Portfolio Quick Import

Import or update all your transactions via one easy-to-use interface
All  Next Launch Portfolio Quick Import

Build Optimal Portfolios

Align your risk with return expectations
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please also check Risk vs Return Analysis. Please also try Balance Of Power module to check stock momentum by analyzing balance of power indicator and other technical ratios.